deltatrials
Completed PHASE2 NCT00049946

Schizophrenia Study In Adults

A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia

Sponsor: GlaxoSmithKline

Conditions Schizophrenia
Interventions risperidone talnetant
Updated 7 times since 2017 Last updated: Aug 14, 2017 Started: Oct 31, 2002 Primary completion: Apr 30, 2003 Completion: Apr 30, 2003

Listed as NCT00049946, this PHASE2 trial focuses on Schizophrenia and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2002, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Sep 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Sep 2017 [monthly]

    Completed PHASE2

    First recorded

Oct 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States, Bellaire, United States, Butner, United States, Cerritos, United States, Chula Vista, United States, Cincinnati, United States, Clementon, United States, Cleveland, United States, Garden Grove, United States, Greenwood, United States and 20 more location s